Pentachloropseudilin disrupts multiple steps of the Toxoplasma gondii lytic cycle, consistent with predicted multi-myosin engagement
The pharmacological targeting of apicomplexan myosins has emerged as a validated antiparasitic strategy, with selective inhibitors of MyoA demonstrating ac